Asia Oncology Drug Market Space Examined in Topical Ken Research Report Now Available at MarketPublishers.com
27 Oct 2015 • by Natalie Aster
LONDON – The Asian oncology drug market is largely driven by surging demand, government investment in healthcare, and competitive pressures. With the emergence of new oncology drug makers in the industry, the revenues grew by 7.6% as against 2013. Each anti-cancer drug market segment is affected by a gamut of various factors like prevalence of specific cancers, price cuts and the number of market players. During 2009-2014, the Asian oncology drug market posted a CAGR of 4.3%. In more developed markets in APAC, including countries like China and Japan, the market players’ offerings are set to be diverse, focused primarily on customised demands. In addition, the sector will likely see expansion in terms of the newer drug forms on the back of growing cancer incidence and rising awareness. The APAC oncology drug market is forecast to grow at a 9% CAGR through to 2019 due to surging affluence of consumers toward healthy lifestyles and treatment of cancer in the recent past.
The region’s oncology drug market is led by the global pharmacos that specialise in marketing patented drug products. Roche is the largest player in the oncology drug market pace, with Pfizer coming second as of 2014. An inclination in the death rates of cancer patients owing to the lack of proper treatment creates a huge opportunity for pharmacos to deliver efficient drugs in the market and thus boosting revenue growth.
Topical report “Asia Oncology Drug Market Outlook to 2019 - Driven by Rising Demand and Intensifying Joint Ventures between Companies” developed by Ken Research Private Ltd provides a comprehensive analysis of Asia’s oncology drug market. It covers different aspects like market size of oncology drugs; market segmentation based on therapeutic class, cancer type, and volume of imports and exports of oncology drugs; market size of the global and domestic players in the regional oncology drug market; market size of the oncology drug markets of India and China; SWOT and Porter’s five force analysis of the Indian and Chinese oncology drug markets; major trends and developments in Asia’s oncology drug market; government regulations in China’s and India’s oncology drug markets; competitive landscape along with detailed company profiles and market shares of the top oncology drug manufacturers in Asia and also in India, China and other countries; macroeconomic factors affecting the oncology drug markets in India and China; and future outlook and forecasts of Asia’s oncology drug market by geography.
Asia Oncology Drug Market Outlook to 2019 - Driven by Rising Demand and Intensifying Joint Ventures between Companies
Date: July, 2015
Price: US$ 1,400.00
More studies by the publisher can be found at Ken Research Private Ltd.